These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16766468)

  • 1. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Vlahos L; Tsiatas ML
    Drug Deliv; 2006; 13(4):269-76. PubMed ID: 16766468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    J Opioid Manag; 2005; 1(1):36-40. PubMed ID: 17315410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
    Borgbjerg FM; Rosenberg J
    Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.
    Mystakidou K; Tsilika E; Tsiatas M; Vlahos L
    Int J Nanomedicine; 2007; 2(1):49-54. PubMed ID: 17722512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis.
    Shaiova L; Lapin J; Manco LS; Shasha D; Hu K; Harrison L; Portenoy RK
    Support Care Cancer; 2004 Apr; 12(4):268-73. PubMed ID: 14750002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral transmucosal fentanyl citrate--OTFC (ACTIQ) #103.
    Gordon D; Schroeder M
    J Palliat Med; 2008 May; 11(4):633-4. PubMed ID: 18454617
    [No Abstract]   [Full Text] [Related]  

  • 13. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
    Vasisht N; Gever LN; Tagarro I; Finn AL
    Clin Drug Investig; 2009; 29(10):647-54. PubMed ID: 19715381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines.
    Aronoff GM; Brennan MJ; Pritchard DD; Ginsberg B
    Pain Med; 2005; 6(4):305-14. PubMed ID: 16083461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fentanyl nasal spray for the treatment of cancer pain.
    Mystakidou K; Panagiotou I; Gouliamos A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1653-9. PubMed ID: 21609189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
    Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
    Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer.
    Blick SK; Wagstaff AJ
    Drugs; 2006; 66(18):2387-93; discussion 2394-5. PubMed ID: 17181383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain.
    Rees E
    Int J Palliat Nurs; 2002 Jun; 8(6):304-8. PubMed ID: 12131825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers.
    Egan TD; Sharma A; Ashburn MA; Kievit J; Pace NL; Streisand JB
    Anesthesiology; 2000 Mar; 92(3):665-73. PubMed ID: 10719944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.